Breaking News

Tweet TWEET

Cynosure and Palomar Announce Date for Stockholder Meetings

         Cynosure and Palomar Announce Date for Stockholder Meetings

PR Newswire

WESTFORD, Mass. and BURLINGTON, Mass., April 24, 2013

WESTFORD, Mass. and BURLINGTON, Mass., April 24, 2013 /PRNewswire/
--Cynosure, Inc. (NASDAQ: CYNO) and Palomar Medical Technologies, Inc.
(NASDAQ: PMTI) today announced that the 2013 Annual Meeting of Cynosure
Stockholders and the Special Meeting of Palomar Stockholders are scheduled to
be held on June 24, 2013. Cynosure and Palomar stockholders of record at the
close of business on May 21, 2013 will be entitled to notice of and to vote at
the respective stockholder meetings.

At the meetings the Cynosure and Palomar stockholders will be asked to approve
the acquisition of Palomar by Cynosure in a transaction valued at
approximately $294 million. The execution of the definitive agreement related
to the transaction was previously announced on March 18, 2013. Assuming
Cynosure and Palomar stockholders approve the transaction, the merger is
expected to close by the end of June 2013.

About Cynosure

Cynosure develops and markets aesthetic treatment systems that are used by
physicians and other practitioners to perform non-invasive and minimally
invasive procedures to remove hair, treat vascular and pigmented lesions,
remove multi-colored tattoos, rejuvenate the skin, liquefy and remove unwanted
fat through laser lipolysis, reduce cellulite and treat onychomycosis.
Cynosure's products include a broad range of laser and other light-based
energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode
lasers, as well as intense pulsed light. Cynosure was founded in 1991. For
corporate or product information, visit Cynosure's website at
www.cynosure.com.

About Palomar

Palomar designs, produces and sells the most advanced cosmetic lasers and
intense pulsed light (IPL) systems to dramatically improve the appearance of
women's and men's skin. For over 15 years, Palomar has pioneered the science
of using lasers and light to improve appearances. As the industry's technology
leader, Palomar has invested in creating cosmetic laser and IPL systems that
put real value in the hands of physicians and other professionals to benefit
consumers. Thousands of physicians worldwide trust and depend on Palomar
technology to not only introduce new aesthetic treatments such as advanced
laser hair removal, laser liposuction, skin resurfacing, acne, laser
treatments for scars, wrinkle treatment, stretch marks (striae), and
photofacials for pigmented and vascular lesions, but to also make them robust,
faster, more powerful, and more comfortable for those being treated. In June
2009, Palomar became the first company to receive a 510(k) over-the-counter
("OTC") clearance from the FDA for a new, patented, home-use, laser device for
the treatment of fine lines and wrinkles around the eyes (periorbital
wrinkles). This OTC clearance allows the PaloVia^® Skin Renewing Laser^® to be
marketed and sold directly to consumers without a prescription. For more
information on Palomar and its products, visit Palomar's website at
www.palomarmedical.com for professional products or palovia.com for consumer
products.

Safe Harbor Statement

This press release contains a forward-looking statement relating to the
expected closing of the merger transaction between Cynosure and Palomar. This
forward-looking statement is neither a promise nor a guarantee, but involves
risks and uncertainties that may individually or mutually impact the matters
herein, and cause actual results, events and performance to differ materially
from such forward-looking statement. These risk factors include, but are not
limited to, failure to receive approval from the stockholders of Palomar or
Cynosure or to satisfy other conditions to the parties' obligations to
complete the merger, the risk that competing offers for Palomar will be made
and/or other factors, which are detailed from time to time in Cynosure's and
Palomar's SEC reports, including their reports on Form 10-K for the year ended
December 31, 2012, any subsequently filed quarterly reports on Form 10-Q and
the Cynosure Registration Statement on Form S-4 (File No. 333-187895). Readers
are cautioned not to place undue reliance on this forward-looking statement,
which speaks only as of the date hereof. Neither Cynosure nor Palomar
undertakes any obligation to release publicly the result of any revisions to
the forward-looking statement that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.

Additional Information about the Proposed Transaction and Where to Find It

In connection with the proposed transaction, Cynosure filed a Registration
Statement on Form S-4 (File No. 333-187895) with the Securities and Exchange
Commission ("SEC") on April 12, 2013. The Registration Statement includes a
joint proxy statement of Cynosure and Palomar that also constitutes a
prospectus of Cynosure. Palomar and Cynosure also plan to file other relevant
documents with the SEC regarding the proposed transaction. INVESTORS ARE URGED
TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS
FILED WITH THE SEC (IF AND WHEN THEY BECOME AVAILABLE) BECAUSE THEY CONTAIN OR
WILL CONTAIN IMPORTANT INFORMATION. You may obtain a free copy of the joint
proxy statement/prospectus and other relevant documents filed by Cynosure and
Palomar with the SEC (if and when they become available) at the SEC's website
at www.sec.gov. You may also obtain these documents by contacting Cynosure's
Investor Relations Department at (617) 542-5300 or CYNO@investorrelations.com,
or by contacting Palomar's Investor Relations Department at (781) 993-2411 or
ir@palomarmedical.com.

Cynosure and Palomar and their respective directors and executive officers and
other members of management and employees may be deemed to be participants in
the solicitation of proxies in respect of the proposed transaction.
Information about Cynosure's directors and executive officers is available in
the joint proxy statement/prospectus under the heading "Information About
Cynosure's Directors, Officers and 5% Stockholders." As of April 5, 2013,
Cynosure's directors and executive officers beneficially owned approximately
2.9 million shares, or 17.1%, of Cynosure's Class A common stock. Information
about Palomar's directors and executive officers is available in Palomar's
proxy statement dated April 4, 2012 for its 2012 Annual Meeting of
Stockholders and in the joint proxy statement/prospectus. As of March 15,
2013, Palomar's directors and executive officers beneficially owned
approximately 2.7 million shares, or 13.1%, of Palomar's common stock.
Additional information regarding the interests of Palomar's directors and
executive officers in the proposed transaction, including information relating
to the acceleration of Palomar equity awards; the election of Joseph P.
Caruso, Palomar's President, Chief Executive Officer and Chairman of the Board
of Directors, as Cynosure's President and Vice Chairman of the Board of
Directors; amendments to existing Palomar employment agreements; a new
employment agreement between Cynosure and Mr. Caruso; indemnification and
insurance matters relating to Palomar directors and executive officers; and
golden parachute compensation, can be found in the joint proxy
statement/prospectus under the heading "Interests of Directors and Executive
Officers of Palomar in the Merger." Investors should read the joint proxy
statement/prospectus carefully before making any voting or investment
decisions. You may obtain free copies of any documents described above from
Cynosure or Palomar using the sources indicated above.

This document shall not constitute an offer to sell or the solicitation of an
offer to buy any securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such
jurisdiction. No offering of securities shall be made except by means of a
prospectus meeting the requirements of Section 10 of the U.S. Securities Act
of 1933, as amended.

Contacts:
Scott Solomon                   Kerry McAnistan
Vice President                  Investor Relations Assistant
Sharon Merrill Associates, Inc. Palomar Medical Technologies, Inc.
617.542.5300                    781-993-2411
cyno@investorrelations.com      ir@palomarmedical.com

SOURCE Cynosure, Inc.

Website: http://www.cynosure.com
 
Press spacebar to pause and continue. Press esc to stop.